Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer

Marinello, Arianna; Tagliamento, Marco; Pagliaro, Arianna; Conci, Nicole; Cella, Eugenia; Vasseur, Damien; Remon, Jordi; Levy, Antonin; Dall’Olio, Filippo Gustavo; Besse, Benjamin

doi:10.1016/j.ctrv.2024.102791

Cancer Treatment Reviews

2024

DOI: 10.1016/j.ctrv.2024.102791

|View full text |Cite

Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer

Arianna Marinello,

Marco Tagliamento,

Arianna Pagliaro

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Chandrasekhar,

Yang,

Demir

et al. 2024

American Journal of Transplantation

View full text Add to dashboard Cite

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Chandrasekhar,

Yang,

Demir

et al. 2024

American Journal of Transplantation

View full text Add to dashboard Cite

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Parisi,

Abdayem,

Tagliamento

et al. 2024

Cancer Treatment Reviews

View full text Add to dashboard Cite

Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives

Hofman

2024

Cancers

View full text Add to dashboard Cite

The targeted therapies and immunotherapies in thoracic oncology, particularly for NS-NSCLC, are associated with an increase in the number of predictive biomarkers to be assessed in routine clinical practice. These treatments are administered thanks to marketing authorization for use in daily practice or are evaluated during clinical trials. Since the molecular targets to be identified are more and more complex and numerous, it is now mandatory to use NGS. NGS can be developed from both tissue and fluid (mainly blood). The blood tests in oncology, so-called “liquid biopsies” (LB), are performed with plasmatic circulating free DNA (cf-DNA) and are complementary to the molecular testing performed with a TB. LB use in lung cancer is associated with international guidelines, but additional algorithms could be set up. However, even if useful for better care of patients, notably with advanced and metastatic NS-NSCLC, until now LB are not often integrated into daily practice, at least in Europe and notably in France. The purpose of this review is to describe the different opportunities and algorithms leading to the identification of the molecular signature of NS-NSCLC, using both tissue and liquid biopsies, and to introduce the principle limitations but also some perspectives in this field.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer

Cited by 3 publications

References 87 publications

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives

Contact Info

Product

Resources

About